Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 15/20 | 0.52 |
| ▸ | DAO | P14920 | 1/20 | 0.52 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.47 |
| ▸ | CYTH3 | O43739 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | EPN1 | Q9Y6I3 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24758142 | 0.82 | HCAR2 (0.37) | HCAR2DAOHCAR3CYTH3BTK | |
| SCHEMBL24117299 | 0.74 | MAPK1 (0.39) | HCAR2HCAR3MEN1KMT2APOLB | |
| Water SCHEMBL1267709 | 0.72 | HCAR2 (0.57) | HCAR2DAOHCAR3CYTH3BTK | |
| SCHEMBL165390 | 0.72 | — | — | |
| Ammonia Solution, Strong SCHEMBL28463590 | 0.71 | HCAR2 (0.55) | HCAR2DAOHCAR3CYTH3BTK | |
| SCHEMBL165389 | 0.70 | — | — | |
| SCHEMBL70577 | 0.70 | HCAR2 (0.59) | HCAR2DAOHCAR3CYTH3BTK | |
| SCHEMBL220072 | 0.68 | — | — | |
| SCHEMBL19987833 | 0.68 | HCAR2 (0.57) | HCAR2DAOHCAR3CYTH3BTK | |
| SCHEMBL20929044 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388601-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12358928-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2025-07-15 | — | — | US | disclosed |
| CN-118994191-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118994190-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-114437105-B | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2024-10-11 | — | — | CN | disclosed |
| US-20240150376-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-20230043400-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230043400-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2023-02-09 | — | — | US | disclosed |
| CN-114437105-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-109071504-B | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2022-03-08 | — | — | CN | disclosed |
| WO-2017136727-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| CN-1016398-B | The pollen that contains pyrazole derivatives generates composite inhibiting | ELLI LILLY & CO (US) | 1992-04-29 | — | — | CN | disclosed |
| US-4966623-A | POLLEN INHIBITION | ACKMANN STEPHEN A (US) | 1990-10-30 | — | — | US | disclosed |
| US-4902808-A | HYBRID, POLLEN FORMATION INHIBITOR | ELI LILLY AND COMPANY (US) | 1990-02-20 | — | — | US | disclosed |
| EP-0177242-B1 | POLLEN FORMATION INHIBITING PYRAZOLES | ELI LILLY AND COMPANY (US) | 1990-01-03 | — | — | EP | disclosed |
| US-4801326-A | PRODUCTION OF HYBRID SEED | ELI LILLY AND COMPANY (US) | 1989-01-31 | — | — | US | disclosed |
| US-4775409-A | PREVENTING POLLEN FORMATION | ELI LILLY AND COMPANY (US) | 1988-10-04 | — | — | US | disclosed |
| EP-0244075-A1 | Gametocidal pyrazoles | ELI LILLY AND COMPANY (US) | 1987-11-04 | — | — | EP | disclosed |
| US-4666504-A | HYBRIDS | ELI LILLY AND COMPANY (US) | 1987-05-19 | — | — | US | disclosed |
| EP-0177242-A2 | Pollen formation inhibiting pyrazoles | ELI LILLY AND COMPANY (US) | 1986-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388601-A1 | Compounds, Compositions and Methods | AURKC, WEE2, ERBB2 | HCAR2 924/4885DAO 1600/4885HCAR3 1171/4885 |
| US-20240150376-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | HCAR2 3504/4885DAO 4017/4885HCAR3 2641/4885 |
| US-12358928-B2 | Compounds, compositions and methods | PIK3CA, PLK1, PIK3CB | HCAR2 3504/4885DAO 4017/4885HCAR3 2641/4885 |
| US-20230043400-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | HCAR2 3504/4885DAO 4017/4885HCAR3 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.